Where is Venrock Healthcare Capital Partners located?

Venrock Healthcare Capital Partners is headquartered in New York, US.

Venrock Healthcare Capital Partners

Venture capital

New York

Also known as Venrock Healthcare Capital Partners EG · Venrock Healthcare Capital Partners XP

★ Follow + Add to CRM ⤳ Find an introduction

✨ Fox Verdict

Fund manager profile

Venrock Healthcare Capital Partners is a venture fund manager based in New York. SEC filings show 5 venture funds on record, most recently Venrock Healthcare Capital Partners XP, L.P. ($500M offering) filed November 2024.

Source: SEC EDGAR Form D filings. Firm website data not yet available.

New York, US

Founded

2018

Last 12 months

2 investments

Tracked investments

What they invest in

from 6 of 6 portfolio companies

Biotech ×6Healthtech ×3AI & Machine Learning ×1

HQs:United States×5

Investments · 6 tracked

founders shown can be your intro path

By year:2026 · 1 2025 · 1 2024 · 13 dated

Maze Therapeuticsmazetx.com in 𝕏NASDAQ: MAZESep 2025

Maze Therapeutics develops precision medicines for common diseases with high unmet need, using its Compass platform based on human genetics and variant functionalization.

AI & Machine LearningBiotechSouth San Francisco, US

Jason Coloma(Chief Executive Officer)in

Co-investorsAndreessen Horowitz ARCH Venture Partners Foresite Capital Frazier Life Sciences GV (Google Ventures)Janus Henderson Investors

Upstream Bioupstreambio.com in 𝕏NASDAQ: UPB

Upstream Bio is a clinical-stage biotechnology company developing verekitug, an antagonist that targets the TSLP receptor to inhibit pro-inflammatory signaling.

BiotechHealthtech

Rand Sutherlandin

Co-investorsAccess Biotechnology Bain Capital Life Sciences Decheng Capital OrbiMed Samsara BioCapital TCG Crossover

Cidara Therapeuticscidara.com in 𝕏

Pharmaceutical company developing medicines and vaccines for patient health and treatment.

BiotechHealthtechSan Diego, US

Jeffrey Stein(Executive Officer, Director)Kevin Judice(Director)Kevin Forrest(Executive Officer)Dirk Thye(Executive Officer)Ken Bartizal(Executive Officer)Paul Daruwala(Executive Officer)

Co-investors5AM Ventures Aisling Capital Bain Capital Life Sciences Frazier Life Sciences RA Capital Vivo Capital +1 more

Clade Therapeutics inApr 2024

BiotechCambridge, US

Chad A. Cowan(Executive Officer, Director)Leandro Vetcher(Executive Officer)Daniel Vasella(Director)Jim Glasheen(Executive Officer, Director)Neil White(Director)

BoardMartin Murphy(Director)

Co-investorsBain Capital Life Sciences Casdin Capital

Kinnate Biopharmakinnate.com

BiotechSan Diego, US

Stephen W. Kaldor(Executive Officer, Director, Promoter)Eric Murphy(Executive Officer, Director)

BoardBret Zbar(Director)Carl Gordon(Director)Michael Rome(Director)

Co-investorsForesite Capital Nextech Invest Janus Henderson Investors RA Capital Viking Global Investors

Lycia Therapeuticslyciatx.com in 𝕏Jun 2026 · $75M

Lycia Therapeutics is a biotechnology company developing LYTAC (Lysosomal Targeting Chimera) therapeutics that bind disease-causing extracellular and cell-surface proteins and route them into the cell's lysosome for degradation.

BiotechHealthtechSouth San Francisco, US

Aetna Wun Trombley(President and CEO)Amy Bachrodt(Chief Financial Officer)Chin Lee(Chief Medical Officer)Steve Staben(Chief Scientific Officer)Sofia Touami(Chief Business Officer)Karen Flick(General Counsel)